This article is more than 5 years old. Information may no longer be current.
Severity of corneal neovascularization may be reduced with topical ranibizumab
Corneal neovascularization may be treated with topical ranibizumab to reduce severity through decrease in the vessel caliber, according to a study.
The prospective, open-label, monocentric, uncontrolled, noncomparative study included 10 eyes of nine patients with corneal neovascularization. Lucentis (ranibizumab, Genentech) was administered 4 times a day for 3 weeks with a follow-up of 16 weeks. Measurements were taken for neovascular area, vessel caliber, area occupied by the corneal neovessels, mean diameter of the corneal neovessels and invasion area.
There was a significant decrease in neovascular area (55.3%, P < .001) for the entire follow-up period, and vessel caliber improved out to week 16 (59%, P < .001).
Disclosure: Giulio Ferrari, MD, has received a grant from the Bietti Eye Foundation. Reza Dana, MD, MSc, MPH, received financial support from Genentech and NIH EY-019098. The other authors have no financial or conflicts of interest to disclose.